Efficacy and Safety of Sonidegib in the Treatment of Multiple Facial Cutaneous Basal Cell Carcinomas with Chronic Renal Insufficiency: A Case Report
Wenwen Jing, Junwu Yang, Zhicheng Gong, Weiqi Lei, Zhenhua Zhang, Wen Bin Rao, Yong Ai · 2026
Read Efficacy and Safety of Sonidegib in the Treatment of Multiple Facial Cutaneous Basal Cell Carcinomas with Chronic Renal Insufficiency: A Case Report by Wenwen Jing, Junwu Yang, Zhicheng Gong, Weiqi Lei, Zhenhua Zhang, Wen Bin Rao, Yong Ai (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13271057.txt.
Description
Wenwen Jing and co-authors report a skin cancer drug working safely despite weak kidneys in a 2026 case paper. Basal cell carcinoma is among the most common skin cancers, and surgery cures most cases. For tumors that cannot be cut out, drugs that block the hedgehog signaling pathway offer an option. Guidance is thin, though, for patients whose kidneys already fail.
Their patient had many basal cell cancers on the face plus chronic renal insufficiency. She was treated with sonidegib, one of the pathway-blocking drugs. The case showed the drug could be given with effect and without wrecking kidney function. The authors present sonidegib as a plausible safe choice for inoperable skin cancer in such patients. They note that wider evidence and guidelines for this group are still lacking.
Catalog record
| CREATOR | Wenwen Jing, Junwu Yang, Zhicheng Gong, Weiqi Lei, Zhenhua Zhang, Wen Bin Rao, Yong Ai |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 15 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |